– GERMANY, Regensburg – numares, appoints Kathy L. Bates, MBA, as a new member of the Supervisory Board with immediate effect. Ms. Bates is Senior Director, Laboratory Services and Partnership Development at Mayo Clinic, in Rochester, Minnesota.
“We are delighted to welcome Kathy to the board,” says Dr. Volker Pfahlert, CEO of numares. “As we continue our focus on North American expansion, the depth of knowledge and relevant experience in the US healthcare will be invaluable to numares.”
Recently, numares and Mayo Clinic Laboratories announced their collaboration to develop new diagnostic tests using the “numares model” – meaning a distinctive nuclear magnetic resonance technology, to identify metabolite constellations for diagnostics.
At the annual general meeting, Ms. Bates was elected to follow Dr. Gerd Grenner, who supported numares as member of the Supervisory Board since 2014 and left his position due to private reasons. The other Board Members, Dr. Schirmers, Dr. Ries and Dr. Kutzner were reelected. Dr. Bernhard Schirmers, Chairman of the Supervisory Board, thanked Dr. Grenner in special recognition of his many years of commitment for his achievements on behalf of the Supervisory Board.
About Kathy Bates
Ms. Bates is the first member of the Supervisory Board from the US. After starting her career in 1994, Ms. Bates completed various leading positions at Mayo Clinic and its partnership organizations. Her competence profile is supplemented by a large pool of experiences serving on the board of directors of Oncospire Genetics Inc. and on a Scientific Advisory Board for Roche Diagnostics Switzerland.
Since 2005 Kathy Bates is Senior Director, Laboratory Services and Partnership Development at Mayo Clinic, leading technology evaluations and strategic business development activities in laboratory diagnostics.
numares, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolic data to develop advanced analytical tests for high-throughput use in clinical diagnostics and life science research. The company’s AXINON system employs nuclear magnetic resonance spectroscopy to create a spectrum standardized by Magnetic Group SignalingTM to evaluate metabolite constellations. MGS is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests are an important pillar in precision medicine to address unmet needs in cardiovascular diseases, nephrology, oncology and neurology.
For more information : https://www.numares.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.